常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
3.19/4.48
|
|
企业价值
129.59B
|
| 资产负债 |
|
每股账面净值
34.99
|
| 现金流量 |
|
现金流量率
0.11
|
| 损益表 |
|
收益
32.00B
|
|
每股收益
20.19
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profitsfor this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China. |

46.78 
